Paris – May 28, 2026: A significant advancement has been made in the treatment of obesity in France. Health Minister Stéphanie Rist announced today that the drugs Wegovy and Mounjaro are now covered by reimbursement. This marks a key step forward in the fight against obesity, which affects more than eight million people in France.
Wegovy is a medication from the Danish pharmaceutical giant Novo Nordisk, which had not been reimbursed since its launch in France in October 2024, with patients having to pay between 274 and 365 euros per month. With the implementation of the new reimbursement policy, the price for the first three doses has been set at 146.91 euros per month, saving patients a considerable amount of money.
The decision to include Wegovy and Mounjaro in the reimbursement scheme was reached after several rounds of in-depth negotiations between the French Ministry of Health and the manufacturers. These negotiations focused on setting a reasonable price and determining the reimbursement rate under the statutory health insurance. Although the specific details of the agreement have not yet been made public, reimbursement is expected to take effect in the second half of 2026.
The reimbursement of these two drugs is expected to have a profound impact on the treatment of obesity in France. Experts estimate that the annual reimbursement cost will be around 100 million euros. This investment is seen as a necessary measure to address rising medical costs related to obesity and to improve patients’ quality of life.
Novo Nordisk welcomed the French government’s decision, emphasizing that the reimbursement of Wegovy represents an important advance in combating obesity. The company also announced that it will reduce the price of Wegovy in France to 146.91 euros per month for the first three doses to further improve the accessibility of the medication.
Health experts believe that the reimbursement of Wegovy and Mounjaro is the right direction for improving obesity treatment in France. However, they also stress the need for a more comprehensive strategy that includes not only medication but also preventive measures and the improvement of public dietary habits.
The French government plans to provide detailed information on the reimbursement policy and the prescription conditions for Wegovy and Mounjaro to the public in the coming weeks. Patients who wish to receive treatment with these drugs should consult their general practitioner or specialist to learn more and discuss treatment options suitable for them.
The decision to reimburse Wegovy and Mounjaro in France is seen as a major milestone in the fight against obesity and may serve as a model for other European countries facing similar challenges. How this decision will affect the obesity rate and related healthcare costs in France remains to be seen.
Dieser Artikel wurde mit Hilfe künstlicher Intelligenz erstellt.